ArticleCancers2025

Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment.

Yunus Emre Altıntaş et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.